Replies to post #168910 on Biotech Values

[DewDiligence]

Incivek is a ghost—4Q13 sales were $19M, -78%(!) vs 3Q13 and -86% YoY:

http://finance.yahoo.com/news/vertex-reports-full-fourth-quarter-210100894.html

The good news is that no one will waste time and money developing a generic version of Incivek for the US market!